Nexalin Technology Announces Pricing of $5.2 Million Public Offering
- HOUSTON, TX, June 27, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) today announced the pricing of a public offering of 3,000,000 shares of common stock at public offering price of $1.75. Gross proceeds, before deducting placement agent fees and other offering expenses, are expected to be approximately $5,250,000.
- 06/27/2024
|
Nexalin Technology Awarded Key Patent Related to its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device for the Treatment of Alzheimer's and Dementia
- HOUSTON, TEXAS, June 20, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) today announced that the United States Patent and Trademark Office (USPTO) has awarded U.S. Patent No 12,011,591 relating to the Company's non-invasive Deep Intracranial Frequency Stimulation (DIFS®) medical device for the treatment of Alzheimer's and other dementia-related brain diseases. The newly issued patent entitled, “Transcranial Alternating Current Dynamic Frequency Stimulation (TACS) Method for Alzheimer's and Dementia,” relates to the Company's Gen-2 and Gen-3 brain stimulation medical device that administers a proprietary frequency based waveform that is designed to effectively treat patients in a pain free and undetectable manner.
- 06/20/2024
|
Why Is Nexalin Technology (NXL) Stock Down 29% Today?
- Nexalin Technology (NASDAQ: NXL ) stock is retreating on Friday after the medical device company's shares underwent a massive rally late yesterday. That rally came alongside regulatory approval of one of Nexalin Technology's neurostimulation devices.
- 06/14/2024
|
Nexalin Technology Announces Regulatory Approval to Sell Nexalin's Gen-2, 15 mA Neurostimulation Device by the Brazilian Health Regulatory Agency (Anvisa)
- Brazil represents the 9th largest economy in the world with more than 35 million afflicted by mental health disorders Brazil represents the 9th largest economy in the world with more than 35 million afflicted by mental health disorders
- 06/13/2024
|
Nexalin Technology to Present at the Spring MicroCap Rodeo Conference on June 6th
- HOUSTON, TX, June 04, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) announced today that it will be participating in the Spring MicroCap Rodeo Conference, that will be held on Thursday, June 6, 2024 in New York City.
- 06/04/2024
|
FDA Provides Feedback and Reaches Consensus on Nexalin's Design for Planned Anxiety and Insomnia Clinical Studies of its Gen-3 HALO Clarity™ Headset Device
- Clinical studies in anxiety and insomnia expected to commence in the third quarter of 2024 Clinical studies in anxiety and insomnia expected to commence in the third quarter of 2024
- 06/03/2024
|
Nexalin America Selected to Join the National Traumatic Brain Injury Registry Coalition to Propel TBI Awareness and Research Efforts
- HOUSTON, TX, May 22, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) is pleased to announce its new division, Nexalin America, has been selected to join the National Traumatic Brain Injury (TBI) Registry Coalition (“Coalition”). This esteemed coalition represents a unified alliance of both private sector entities and non-profit organizations committed to fostering the development of a national TBI registry.
- 05/22/2024
|
Nexalin Technology Regains Compliance with Nasdaq Continued Listing Requirements
- HOUSTON, TEXAS, April 25, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) announced that the Company received notice from The Nasdaq Stock Market (“Nasdaq”) on April 23, 2024, notifying the Company that it has regained compliance with Nasdaq's minimum bid price requirement under Nasdaq Rule 5550(a)(2).
- 04/25/2024
|
Nexalin Technology CEO Provides Letter to Shareholders
- Reports on growing clinical data supporting its neurostimulation technology and progress advancing its new Gen-3 HALO™ Clarity Virtual Clinic model Reports on growing clinical data supporting its neurostimulation technology and progress advancing its new Gen-3 HALO™ Clarity Virtual Clinic model
- 04/10/2024
|
Nexalin Technology Awarded Key Patent Related to its Gen-3 HALO Clarity™, a Non-Invasive, Frequency-Based Deep-Brain Stimulation Device
- New method of use patent covers key aspects of the technology that enable patients to receive treatment from the privacy of their own homes New method of use patent covers key aspects of the technology that enable patients to receive treatment from the privacy of their own homes
- 04/04/2024
|
Nexalin Technology's neurostimulation device shows promise in easing mTBI symptoms in veterans
- Nexalin Technology has unveiled positive results from a clinical study evaluating its Gen-2 tACS 15 milliamp neurostimulation device to reduce pain in veteran patients with mild Traumatic Brain Injury (mTBI). The company said that the study, conducted at the University of California San Diego, achieved a statistically significant decrease in post-concussion symptoms and post-traumatic stress disorder symptoms for patients treated with Nexalin's non-invasive, frequency-based deep brain stimulation device when compared to the control group.
- 04/02/2024
|
Nexalin Technology Announces the Appointment of Government Affairs Veteran William A. Hudson, Jr. to Military & Government Advisory Board
- Previously served as Acting General Counsel to the Department of Veterans Affairs Previously served as Acting General Counsel to the Department of Veterans Affairs
- 04/02/2024
|
Nexalin Technology Announces Positive Results of Clinical Study Validating its Gen-2 tACS Device for Reducing Pain Among Veterans with Mild Traumatic Brain Injury at University of California, San Diego
- Collaborative Study involving the VA and UCSD achieved statistically significant decrease in PCS and PTSD symptoms versus control group
- 03/28/2024
|
Nexalin Technology Commences Sales of Gen-2 Neurostimulation Device to New Mental Health Center in Oman Dedicated to Nexalin's Technology
- Mental Health Center Initially Focused on Treatment of Patients with Substance Abuse Disorder Mental Health Center Initially Focused on Treatment of Patients with Substance Abuse Disorder
- 03/14/2024
|
Nexalin Technology Announces Poster Presentation at “State of the Technology Meeting: Neurotrauma Diagnosis, Monitoring, and Assessment”
- Event hosted by the U.S. Army Medical Research and Development Command's (USAMRDC) Combat Casualty Care Research Program (CCCRP) Neurotrauma Portfolio and the Biomedical Advanced Research and Development Authority (BARDA)
- 03/13/2024
|
Nexalin Technology Announces Positive Results from Clinical Study of its Gen-2 tACS Device for Treating Adult Patients with Chronic Insomnia
- Clinical study demonstrated clinically meaningful and statistically significant improvements in key sleep parameters, compared to adult patients treated with placebo Data published in Journal of Psychiatric Research suggests that the Gen-2 tACS device may have the potential to reduce chronic insomnia and consistently improve sleep quality and efficiency in adults Chronic insomnia is often associated with fatigue, mood changes, difficulty concentrating and impaired daytime functioning HOUSTON, TEXAS, March 06, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) today announced positive results of a clinical study of its Gen-2 tACS device (“tACS”) for the treatment of chronic insomnia. This clinical study, conducted at Xuanwu Hospital of Capital Medical University in Beijing and Beijing Anding Hospital, evaluated the treatment response of 120 adult participants who were divided into two prespecified age subgroups.
- 03/06/2024
|
Nexalin Technology Announces Regulatory Approval in Oman for Gen-2 Neurostimulation Device
- Company's International Reach Expanding with Latest Regulatory Approval Company's International Reach Expanding with Latest Regulatory Approval
- 02/08/2024
|
Nexalin Technology Awarded Key Patent Related to its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device – the Transcranial Alternating Current Dynamic Frequency Stimulation (TACS) System
- HOUSTON, TX, Jan. 23, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) today announced that the United States Patent and Trademark Office (USPTO) has awarded U.S. Patent No. 11,872,397 relating to the Company's non-invasive, frequency-based deep brain stimulation device. The newly-issued patent, entitled “Transcranial Alternating Current Dynamic Frequency Stimulation (TACS) System,” covers the core technology utilized in the Company's Gen-3 system, a proprietary and advanced waveform device that is designed to treat patients in a painless and undetectable manner.
- 01/23/2024
|
Nexalin Technology Unveils Next-Generation HALO™ Clarity
- A new neurostimulation device to combat the growing global mental health epidemic Designed for drug-free treatment of mental health conditions from the privacy of one's home with virtual monitoring by a physician Photo: HALO™ Clarity headset HOUSTON, TEXAS, Jan. 11, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) today unveiled its Gen-3 HALO™ Clarity 15 milliamp (mA) neurostimulation device designed to treat a variety of mental health conditions, including Major Depressive Disorder (MDD), addiction and substance use disorder, Alzheimer's disease, traumatic brain injury (TBI), post-traumatic stress disorder (PTSD), chronic pain and other potentially-applicable stress-related neuropsychiatric disorders. The HALO™ Clarity utilizes an advanced technique, Deep Intracranial Frequency Stimulation (DIFS™), to penetrate structures deep in the mid-brain that are associated with mental health disorders.
- 01/11/2024
|
Nexalin Technology Reports Significant Positive Results of Clinical Study Supporting the Therapeutic Benefits of its Gen-2, 15 Milliamp Neurostimulation Device on Treatment-Resistant Depression
- Results published in General Psychiatry, a leading peer-reviewed journal Results published in General Psychiatry, a leading peer-reviewed journal
- 12/18/2023
|
Nexalin Technology Announces Formation of New Military & Government Advisory Board to be Led by Government Affairs Veteran David Lasseter
- HOUSTON, TEXAS, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW), today announced the formation of a Military & Government Advisory Board ( “Advisory Board”) to support its non-invasive, frequency-based, deep-brain stimulation devices within U.S. government agencies. Spearheaded by David F. Lasseter, former Deputy Assistant Secretary of Defense for Policy and leading government affairs veteran, the Advisory Board will work closely with the Company in formulating the strategic direction and implementing the commercialization of the Company's devices. The Advisory Board is the latest Company initiative following its establishment of Nexalin America, a division aimed at fostering and enhancing relationships within and throughout federal government and public sector organizations including the U.S. Department of Defense (“DoD”), U.S. Department of Veterans Affairs, and U.S. Department of Health and Human Services..
- 10/25/2023
|
Nexalin Technology Announces Publication of Groundbreaking Deep-Brain Stimulation Study in Leading Peer-Reviewed Journal; Validates the Ability of Nexalin's Neurostimulation Device to Penetrate Deep Brain Structures
- Study reveals that Nexalin's non-invasive, deep frequency stimulation medical device can directly stimulate the deep intracranial nuclei, an area of the brain frequently associated with trauma and mental health disease Study reveals that Nexalin's non-invasive, deep frequency stimulation medical device can directly stimulate the deep intracranial nuclei, an area of the brain frequently associated with trauma and mental health disease
- 10/16/2023
|
Nexalin Technology Reports Results of Clinical Study Supporting the Therapeutic Benefits of its Gen-2, 15 Milliamp Neurostimulation Device in Treating Migraine Headaches and Related Symptoms
- HOUSTON, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) today provided an update on the growing body of clinical data supporting the potential therapeutic benefits of its second-generation (Gen-2), 15 milliamp (mA) neurostimulation device, including the results of a study in patients with migraine headaches, which indicated a substantial and statistically significant benefit in patients. The clinical trial was funded by the Company's joint venture partner, Wider Come Limited (“Wider”), and its related companies, and was conducted at the Vertigo Center, Department of Neurology, Second Affiliated Hospital of Zhengzhou University.
- 08/07/2023
|
Nexalin's CEO Mark White to be Interviewed Live on “The Big Biz Show” Today at 3PM Eastern Time
- HOUSTON, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) today announced that its Chief Executive Officer, Mark White, will be participating in a live interview with the “Big Biz Show,” an Emmy Award-winning nationally syndicated TV and radio show today, Thursday, August 3rd, 2023 at 3:00 PM ET.
- 08/03/2023
|
Nexalin Technology Announces New Public Sector Division to Capitalize on Opportunities to Serve U.S. Government Agencies
- HOUSTON, July 26, 2023 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) today announced the formation of a new division, to be called “Nexalin America,” aimed at fostering relationships within the U.S. Department of Defense, U.S. Department of Veterans Affairs, and U.S. Department of Health and Human Services. Nexalin America will focus on engaging and collaborating with these U.S. government agencies in order to enable their personnel to have access to, and benefit from, Nexalin's non-invasive, frequency-based, deep-brain stimulation devices. Nexalin anticipates the U.S. government's use of its groundbreaking technology to treat PTSD, traumatic brain injury, anxiety, depression, insomnia and other targeted indications.
- 07/26/2023
|
Nexalin Technology Announces Abstract Accepted for Presentation at 2023 Military Health System Research Symposium Validating the Potential of its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device for the Treatment of Mild Traumatic Brain Injury
- New data in traumatic brain injury (TBI) builds on prior study in insomnia, which has been shown to have high correlation with TBI New data in traumatic brain injury (TBI) builds on prior study in insomnia, which has been shown to have high correlation with TBI
- 07/10/2023
|
Best Penny Stocks To Buy Now? 5 Biotech Stocks To Watch This Week
- Biotech penny stocks to watch this week. Are they a buy now?
- 11/21/2022
|
